Literature DB >> 30543479

Early Detection and Treatment of Subclinical Lymphedema in Patients with Breast Cancer.

Aslı Gençay Can1, Emel Ekşioğlu1, Fatma Aytül Çakçı1.   

Abstract

Background: Early identification and treatment of subclinical lymphedema may prevent development of advanced stages and its related complications. We aimed to detect subclinical lymphedema and to evaluate the effects of early treatment program on the development of clinical lymphedema, upper extremity functions, and quality of life in patients with subclinical lymphedema. Methods and
Results: Twenty-five women who were diagnosed having subclinical lymphedema were enrolled in the study. The patients were informed about lymphedema and its risk factors, and skin care and exercises to prevent the development of lymphedema. Self-reported symptoms, arm volumes, upper extremity functions, quality of life were evaluated before and after treatment. Tightness and numbness were found to have a good correlation with affected arm volume. Volume of the affected arm, percentage volume difference between the arms, upper extremity functions, and quality-of-life scores improved significantly at the end of the treatment. Conclusions: It is crucial to have early detection and treatment of subclinical lymphedema to prevent the development of established lymphedema in breast cancer survivors. Information about lymphedema and its risk factors, skin care, and home-based specific exercise program improves self-reported symptoms, volume measurements, functioning, and quality of life in patients with subclinical lymphedema.

Entities:  

Keywords:  breast cancer; early detection; early treatment; subclinical lymphedema

Mesh:

Year:  2018        PMID: 30543479     DOI: 10.1089/lrb.2018.0033

Source DB:  PubMed          Journal:  Lymphat Res Biol        ISSN: 1539-6851            Impact factor:   2.589


  6 in total

1.  Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging.

Authors:  Melissa B Aldrich; John C Rasmussen; Sarah M DeSnyder; Wendy A Woodward; Wenyaw Chan; Eva M Sevick-Muraca; Elizabeth A Mittendorf; Benjamin D Smith; Michael C Stauder; Eric A Strom; George H Perkins; Karen E Hoffman; Melissa P Mitchell; Carlos H Barcenas; Lynn E Isales; Simona F Shaitelman
Journal:  Breast Cancer Res Treat       Date:  2022-07-10       Impact factor: 4.624

2.  From Bench to Bedside: The Role of a Multidisciplinary Approach to Treating Patients with Lymphedema.

Authors:  Rachel Lentz; Christina Shin; Zoe Bloom; Kimiko Yamada; Young-Kwon Hong; Alex K Wong; Ketan Patel
Journal:  Lymphat Res Biol       Date:  2021-02-05       Impact factor: 2.589

3.  Comparison of Staging Systems to Assess Lymphedema Caused by Cancer Therapies, Lymphatic Filariasis, and Podoconiosis.

Authors:  Janet Douglass; Louise Kelly-Hope
Journal:  Lymphat Res Biol       Date:  2019-10-04       Impact factor: 2.589

4.  A Web- and Mobile-Based Intervention for Women Treated for Breast Cancer to Manage Chronic Pain and Symptoms Related to Lymphedema: Results of a Randomized Clinical Trial.

Authors:  Mei Rosemary Fu; Deborah Axelrod; Amber A Guth; Joan Scagliola; Kavita Rampertaap; Nardin El-Shammaa; Jeanna M Qiu; Melissa L McTernan; Laura Frye; Christopher S Park; Gary Yu; Charles Tilley; Yao Wang
Journal:  JMIR Cancer       Date:  2022-01-17

5.  Integrating Symptoms Into the Diagnostic Criteria for Breast Cancer-Related Lymphedema: Applying Results From a Prospective Surveillance Program.

Authors:  Cheryl L Brunelle; Sacha A Roberts; Nora K Horick; Tessa C Gillespie; Jamie M Jacobs; Kayla M Daniell; George E Naoum; Alphonse G Taghian
Journal:  Phys Ther       Date:  2020-12-07

6.  Accuracy, Sensitivity, and Specificity of the LLIS and ULL27 in Detecting Breast Cancer-Related Lymphedema.

Authors:  Michelle Coriddi; Leslie Kim; Leslie McGrath; Elizabeth Encarnacion; Nicholas Brereton; Yin Shen; Andrea V Barrio; Babak Mehrara; Joseph H Dayan
Journal:  Ann Surg Oncol       Date:  2021-07-15       Impact factor: 5.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.